Fast Track Designation Awarded to Coramitug in 1,280-Patient ATTR-CM Phase 3 Trial
FDA has granted Fast Track designation to coramitug, a Phase 3 monoclonal antibody targeting ATTR amyloidosis with cardiomyopathy, in the 1,280-patient CLEOPATTRA trial scheduled through 2029. Prothena stands to receive up to $1.2 billion in milestones, including $150 million earned to date.
1. Fast Track Designation and Strategic Impact
The U.S. FDA has granted Fast Track designation to coramitug for treatment of ATTR amyloidosis with cardiomyopathy. This status is designed to facilitate development and expedite regulatory review of coramitug, potentially accelerating its path to market if clinical milestones are met.
2. Phase 3 CLEOPATTRA Trial Details
Coramitug is being evaluated in the Phase 3 CLEOPATTRA trial involving approximately 1,280 participants and targeting primary completion in 2029. The multicenter study will assess efficacy and safety endpoints in patients receiving standard of care therapies alongside coramitug.
3. Financial Considerations under Novo Nordisk Deal
Under Prothena’s licensing agreement with Novo Nordisk, Prothena is eligible for up to $1.2 billion in milestone and sales payments, of which $150 million has been received. Further payments depend on clinical progress and commercial sales achievements once coramitug reaches the market.
4. Coramitug Mechanism and Potential Benefits
Coramitug is a humanized monoclonal antibody designed to clear misfolded transthyretin amyloid through phagocytosis, a mechanism distinct from current stabilizers or production inhibitors. Phase 2 data showed significant NT-proBNP reductions and echocardiographic improvements, supporting its potential as an amyloid-depleting therapy.